APLT News and Press, Applied Therapeutics Inc. From 08/27/21

Gainers: Support.com SPRT +173%. NeuroMetrix (NASDAQ:NURO) +90%. Navios Maritime Acquisition NNA +56%. Vinco Ventures (NASDAQ:BBIG) +49%. Aterian (NASDAQ:ATER) +31%. Marin Software Incorporated (NASDAQ:MRIN) +29%. Gambling.com Group GAMB +29%. Bill.com BILL +28%. Meta Mate...

Gainers: NeuroMetrix (NASDAQ:NURO) +54%, Reneo Pharmaceuticals (NASDAQ:RPHM) +24%, Neoleukin Therapeutics (NASDAQ:NLTX) +21%, Chembio Diagnostics (NASDAQ:CEMI) +17%, InspireMD (NASDAQ:NSPR) +14%. Losers: Cassava Sciences (NASDAQ:SAVA) -28%, Applied Ther...

NDA submission for AT-007 in Galactosemia expected in Q3 2021; commercial preparations ongoing Ended Q2 2021 with a strong balance sheet with $125.6 million in cash and cash equivalents and short-term investments NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Applied Therapeuti...

NEW YORK, June 28, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the Company ha...

~1 in 5 people with diabetes or pre-diabetes have Diabetic Cardiomyopathy, a serious and progressive disease that limits the heart’s ability to function People with diabetes or pre-diabetes who have Diabetic Cardiomyopathy are at high risk for developing overt heart fai...

NEW YORK, June 21, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced a Product Theater p...

syahrir maulana/iStock via Getty Images Applied Therapeutics (APLT) has added ~6.8% in the pre-market after the company announced that the FDA has granted the Fast Track designation to AT-007 for the treatment of Galactosemia, a rare metabolic disorder. Fast Track designation is des...

NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food ...

NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will p...

NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will pr...